{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:53:12Z","timestamp":1776462792699,"version":"3.51.2"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI116596-01"],"award-info":[{"award-number":["1R01AI116596-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018813","name":"Optimer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100570"],"award-info":[{"award-number":["82100570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019398","name":"Beijing Friendship Hospital, Capital Medical University","doi-asserted-by":"publisher","award":["YYZZ202027"],"award-info":[{"award-number":["YYZZ202027"]}],"id":[{"id":"10.13039\/501100019398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.biopha.2023.115489","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T16:16:43Z","timestamp":1694794603000},"page":"115489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice"],"prefix":"10.1016","volume":"167","author":[{"given":"Qianyun","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-3356","authenticated-orcid":false,"given":"Zitong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weishu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric U.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Suzanne","family":"Sears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciaran P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jiph.2022.06.011","article-title":"Global trends in gut microbiota and clostridioides difficile infection research: a visualized study","volume":"15","author":"Li","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.biopha.2023.115489_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mib.2016.11.006","article-title":"The emerging metabolic view of Clostridium difficile pathogenesis","volume":"35","author":"Hryckowian","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2023.115489_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2023.115489_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211016248","article-title":"Epidemiology of community-acquired and recurrent Clostridioides difficile infection","volume":"14","author":"Fu","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115489_bib5","first-page":"134","article-title":"Current treatment options for severe clostridium difficile-associated disease","volume":"4","author":"Shen","year":"2008","journal-title":"Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115489_bib6","first-page":"23","article-title":"Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection","volume":"3","author":"Spigaglia","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115489_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00157-22","article-title":"Host immunity and immunization strategies for clostridioides difficile infection","author":"Naz","year":"2023","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2023.115489_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092578","article-title":"The systemic inflammatory response to Clostridium difficile infection","volume":"9","author":"Rao","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2023.115489_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.gastro.2007.06.063","article-title":"Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand","volume":"133","author":"Kim","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib10","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1053\/j.gastro.2007.03.101","article-title":"Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis","volume":"132","author":"Cottrell","year":"2007","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.biopha.2023.115489_bib11","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1073\/pnas.0402693101","article-title":"Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation","volume":"101","author":"Anton","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2023.115489_bib12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/j.gastro.2023.02.046","article-title":"Host sorbitol and bacterial sorbitol utilization promote clostridioides difficile infection in inflammatory bowel disease","volume":"164","author":"Yang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.115489_bib14","doi-asserted-by":"crossref","first-page":"29791","DOI":"10.1038\/srep29791","article-title":"Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115489_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691480","article-title":"Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice","volume":"12","author":"Bruscoli","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115489_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756283X11405250","article-title":"Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease","volume":"4","author":"Williams","year":"2011","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115489_bib17","first-page":"211","article-title":"Corticosteroids in the treatment of pseudomembranous colitis: a report of 3 cases","volume":"5","author":"Sykes","year":"2012","journal-title":"Gastroenterol. Res."},{"issue":"4","key":"10.1016\/j.biopha.2023.115489_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/adc.88.4.342","article-title":"Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis","volume":"88","author":"Cavagnaro","year":"2003","journal-title":"Arch. Dis. Child"},{"issue":"10","key":"10.1016\/j.biopha.2023.115489_bib19","doi-asserted-by":"crossref","first-page":"ofab419","DOI":"10.1093\/ofid\/ofab419","article-title":"Corticosteroids do not increase the likelihood of primary clostridioides difficile infection in the setting of broad-spectrum antibiotic use","volume":"8","author":"Carlson","year":"2021","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115489_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/phar.1914","article-title":"Evaluation of risk factors for clostridium difficile infection in hematopoietic stem cell transplant recipients","volume":"37","author":"Scardina","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2023.115489_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anaerobe.2014.07.010","article-title":"Corticosteroid use is associated with a reduced incidence of Clostridium difficile-associated diarrhea: a retrospective cohort study","volume":"30","author":"Wojciechowski","year":"2014","journal-title":"Anaerobe"},{"issue":"9","key":"10.1016\/j.biopha.2023.115489_bib22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/ajg.2010.142","article-title":"Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease","volume":"105","author":"Das","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115489_bib23","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.biopha.2023.115489_bib24","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2022.07.086","article-title":"AGA clinical practice update on management of refractory celiac disease: expert review","volume":"163","author":"Green","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2023.115489_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474124.2019.1621745","article-title":"Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis","volume":"13","author":"Salice","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"21","key":"10.1016\/j.biopha.2023.115489_bib27","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2023.115489_bib28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2008.09.002","article-title":"A mouse model of Clostridium difficile-associated disease","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.biopha.2023.115489_bib29","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1128\/AAC.48.10.3975-3979.2004","article-title":"Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters","volume":"48","author":"Anton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.biopha.2023.115489_bib30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/ibd.20489","article-title":"5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane\/dextran sulfate sodium-induced colitis","volume":"14","author":"Clapper","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115489_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004405.pub4","article-title":"Corticosteroids for acute bacterial meningitis","author":"Brouwer","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115489_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/2110-5820-1-7","article-title":"Corticosteroids for severe sepsis: an evidence-based guide for physicians","volume":"1","author":"Annane","year":"2011","journal-title":"Ann. Intensive Care"},{"issue":"5","key":"10.1016\/j.biopha.2023.115489_bib34","doi-asserted-by":"crossref","first-page":"e02112","DOI":"10.1128\/AAC.02112-17","article-title":"Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to clostridium difficile colonization in mice","volume":"62","author":"Ajami","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.biopha.2023.115489_bib35","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/AAC.02783-14","article-title":"Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum","volume":"58","author":"Koon","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2023.115489_bib36","unstructured":"Boston University Research Compliance Research Committee, Administration Of Drugs and Experimental Compounds in Mice and Rats (IACUC) _ Research Support.html \u3008https:\/\/www.bu.edu\/researchsupport\/forms-policies\/administration-of-drugs-and-experimental-compounds-in-mice-and-rats\/\u3009."},{"key":"10.1016\/j.biopha.2023.115489_bib37","article-title":"5-Aminosalicylic acid inhibits acute clostridium difficile toxin A-induced colitis in rats","volume":"2014","author":"Vigna","year":"2014","journal-title":"Int. J. Inflam."},{"issue":"2","key":"10.1016\/j.biopha.2023.115489_bib38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","article-title":"Higher incidence of clostridium difficile infection among individuals with inflammatory bowel disease","volume":"153","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"issue":"27","key":"10.1016\/j.biopha.2023.115489_bib39","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.3748\/wjg.v23.i27.4986","article-title":"Management of inflammatory bowel disease with Clostridium difficile infection","volume":"23","author":"D\u2019Aoust","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115489_bib40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ajg.2016.187","article-title":"Recurrence of clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study","volume":"111","author":"Razik","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115489_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Pharm. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115489_bib42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ibd.21514","article-title":"Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics\/immunomodulators?","volume":"17","author":"Yanai","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115489_bib43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J. Crohns Colitis"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223012878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223012878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:10:05Z","timestamp":1776460205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223012878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"alternative-id":["S0753332223012878"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115489","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115489"}}